Compound Guides
Reference notes on individual research peptides: structure, sequence, documented in vitro literature and handling.
Articles in Compound Guides
- Research noteCompound Guides
Semax Peptide: Structure, ACTH Origin and the Research Record
Semax is a synthetic heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro, derived from adrenocorticotropic hormone with a Pro-Gly-Pro tail added for stability. The literature describes it under two names that look contradictory but refer to the same molecule. Published chemistry shows that acetylating its N-terminus changes copper coordination and removes a protective effect in a cell model, so N-acetyl Semax is a different compound. This guide covers the structure and naming, the preclinical record, the limits of the human reports, and what our certificate does and does not establish.
November 8, 2026 - Research noteCompound Guides
Selank Peptide: Molecular Structure, Mechanism, and Research Overview
Selank is a synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, built from the immunoglobulin fragment tuftsin with a Pro-Gly-Pro extension added to slow its breakdown. Its formula, molecular weight and CAS number are in PubChem, so a certificate can be checked against a public record. The mechanism research is mostly preclinical and not settled: a positive allosteric effect on GABA binding is proposed, yet a human cell line showed no direct transcriptional effect. This guide covers the structure, the evidence and its limits, and what our Selank certificate does and does not establish.
November 7, 2026 - Research noteCompound Guides
IGF-1 LR3: Structure, Binding-Protein Affinity and the Research Record
IGF-1 LR3, or Long-[Arg3]-IGF-I, is a recombinant analogue of insulin-like growth factor-I with a 13-amino-acid N-terminal extension and arginine in place of glutamate at position 3. NMR work shows the folded core is essentially that of IGF-I, with the differences at the N-terminus, where IGF-binding proteins make contact. Its greater potency is not intrinsic: without binding proteins present it has been reported as less potent than native IGF-I. This guide covers the structure, the binding-protein and receptor evidence, laboratory uses, and our certificate for lot PPL-IG1-1.
November 7, 2026 - Research noteCompound Guides
KLOW Peptide Blend: Composition, Laboratory Analysis and Published Research
KLOW is a lyophilised blend of four peptides, labelled 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 and 10 mg KPV. Published research covers the compounds separately; a PubMed search on November 7, 2026 found no study of the four-component combination. Our current lot's certificate identifies and quantifies each component, shows that the headline purity is an average of four separate purities, and finds that the component labelled TB-500 has the mass of full-length thymosin β4.
November 7, 2026 - Research noteCompound Guides
KPV Peptide: Molecular Structure, Mechanisms and Published Research
KPV (Lys-Pro-Val, α-MSH 11-13) is a 342 Da tripeptide cut from α-melanocyte-stimulating hormone. Published research consists of cell-culture experiments, mostly measuring NF-κB activity, and rodent or rabbit models, mostly of colitis; uptake through the PepT1 transporter and partial independence from melanocortin receptors are reported. A PubMed and ClinicalTrials.gov search on November 7, 2026 located no controlled human trial of unmodified KPV. This guide separates KPV from its analogues and formulations and shows what our certificates measure.
November 7, 2026